Vakzine Projekt Management GmbH - Product Pipeline Review - 2014

Date: June 10, 2014
Pages: 24
Price:
US$ 1,500.00 US$ 1,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V614D8DE228EN
Leaflet:

Download PDF Leaflet

Vakzine Projekt Management GmbH - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Vakzine Projekt Management GmbH - Product Pipeline Review - 2014’, provides an overview of the Vakzine Projekt Management GmbH’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Vakzine Projekt Management GmbH’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope
  • The report provides brief overview of Vakzine Projekt Management GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vakzine Projekt Management GmbH’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vakzine Projekt Management GmbH’s pipeline products
Reasons to buy
  • Evaluate Vakzine Projekt Management GmbH’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vakzine Projekt Management GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vakzine Projekt Management GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vakzine Projekt Management GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vakzine Projekt Management GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Explore the dormant and discontinued projects of Vakzine Projekt Management GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Vakzine Projekt Management GmbH SnapshotVakzine Projekt Management GmbH OverviewKey InformationKey FactsVakzine Projekt Management GmbH - Research and Development OverviewKey Therapeutic AreasVakzine Projekt Management GmbH - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyPipeline Products - Out-Licensed ProductsOut-Licensed Products/Combination Treatment ModalitiesVakzine Projekt Management GmbH - Pipeline Products GlanceVakzine Projekt Management GmbH - Clinical Stage Pipeline ProductsPhase II Products/Combination Treatment ModalitiesVakzine Projekt Management GmbH - Early Stage Pipeline ProductsPreclinical Products/Combination Treatment ModalitiesVakzine Projekt Management GmbH - Drug ProfilesVPM-1002Product DescriptionMechanism of ActionR&D ProgressVPM-2001Product DescriptionMechanism of ActionR&D ProgressVPM-5001Product DescriptionMechanism of ActionR&D ProgressVakzine Projekt Management GmbH - Pipeline AnalysisVakzine Projekt Management GmbH - Pipeline Products by TargetVakzine Projekt Management GmbH - Pipeline Products by Route of AdministrationVakzine Projekt Management GmbH - Pipeline Products by Molecule TypeVakzine Projekt Management GmbH - Pipeline Products by Mechanism of ActionVakzine Projekt Management GmbH - Recent Pipeline UpdatesVakzine Projekt Management GmbH - Dormant ProjectsVakzine Projekt Management GmbH - Locations And SubsidiariesHead OfficeAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer

LIST OF TABLES

Vakzine Projekt Management GmbH, Key InformationVakzine Projekt Management GmbH, Key FactsVakzine Projekt Management GmbH - Pipeline by Indication, 2014Vakzine Projekt Management GmbH - Pipeline by Stage of Development, 2014Vakzine Projekt Management GmbH - Monotherapy Products in Pipeline, 2014Vakzine Projekt Management GmbH - Out-Licensed Products in Pipeline, 2014Vakzine Projekt Management GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2014Vakzine Projekt Management GmbH - Phase II, 2014Vakzine Projekt Management GmbH - Preclinical, 2014Vakzine Projekt Management GmbH - Pipeline by Target, 2014Vakzine Projekt Management GmbH - Pipeline by Route of Administration, 2014Vakzine Projekt Management GmbH - Pipeline by Molecule Type, 2014Vakzine Projekt Management GmbH - Pipeline Products by Mechanism of Action, 2014Vakzine Projekt Management GmbH - Recent Pipeline Updates, 2014Vakzine Projekt Management GmbH - Dormant Developmental Projects,2014

LIST OF FIGURES

Vakzine Projekt Management GmbH - Pipeline by Top 10 Indication, 2014Vakzine Projekt Management GmbH - Pipeline by Stage of Development, 2014Vakzine Projekt Management GmbH - Monotherapy Products in Pipeline, 2014Vakzine Projekt Management GmbH - Pipeline by Top 10 Target, 2014Vakzine Projekt Management GmbH - Pipeline by Top 10 Molecule Type, 2014
Skip to top


Recardio GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 24 pages
Pharmedartis GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 24 pages
ElexoPharm GmbH - Product Pipeline Review - 2015 US$ 1,200.00 Feb, 2015 · 24 pages
BioCrea GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 24 pages
Provecs Medical GmbH - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 19 pages

Ask Your Question

Vakzine Projekt Management GmbH - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: